Biogen Inc. (BIIB)
BIIB trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/0000875045-26-000013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BIIB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000875045 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $9.9B |
| Net income | $1.3B |
| Operating income | Not in SEC XBRL data |
| Net margin | 13.1% |
| Operating margin | Operating income not reported |
| Revenue growth | +2.2% |
| Cash | $3.0B |
| Total assets | $29.4B |
| P/E (computed) | 28.8× |
| P/S (computed) | 3.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-28 |
| Cash and burn | $1.3B cash; operating cash flow $561.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 147,820,223 (2026-10-26); 146,702,272 a year earlier; 144,898,112 three years earlier. | Cover page 2026-10-26 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-02-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $585, sold $905K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $2.8B | -$20.6M | $640.8M | $1.3B | $7.3B | $10.3B | 10-Q 2026-10-28 |
| Q2 2026 2026-06-30 | $2.7B | $97.5M | $448.9M | $1.3B | $7.3B | $10.0B | 10-Q 2026-07-29 |
| Q1 2026 2026-03-31 | $2.5B | $319.5M | $645.5M | $3.4B | $6.3B | $9.9B | 10-Q 2026-04-29 |
| Q4 2025 2025-12-31 | $2.3B | -$48.9M | $511.9M | $3.0B | $6.3B | $9.9B | 10-K 2026-02-06 |
| Q3 2025 2025-09-30 | $2.5B | $466.5M | $1.3B | $3.9B | $6.3B | $10.1B | 10-Q 2026-10-28 |
| Q2 2025 2025-06-30 | $2.6B | $634.8M | $160.9M | $2.8B | $6.3B | $10.0B | 10-Q 2026-07-29 |
| Q1 2025 2025-03-31 | $2.4B | $240.5M | $259.3M | $2.6B | $4.5B | $9.8B | 10-Q 2026-04-29 |
| Q4 2024 2024-12-31 | $2.5B | $266.7M | $760.9M | $2.4B | $4.5B | $9.7B | 10-K 2026-02-06 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2025-05-08 |
| Latest annual report | 10-K | 2026-02-06 |
| Latest quarterly / interim | 10-Q | 2026-10-28 |
| Latest current report | 8-K | 2026-10-28 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.0% |
| 1 month | +10.7% |
| 3 months | +20.3% |
| Year to date | +44.0% |
| 1 year | +53.8% |
| From 52-week high | -0.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RVMD | Revolution Medicines Inc. | $166.87 | -3.15% | $36.1B |
| ARGX | argenx SE | $950.95 | -0.95% | $59.0B |
| BNTX | BioNTech SE American Depositary Share | $85.26 | -0.40% | $21.4B |
| NBIX | Neurocrine Biosciences Inc. | $165.31 | -1.25% | $16.7B |
| EXEL | Exelixis Inc. | $67.10 | -2.75% | $16.4B |
| MRNA | Moderna Inc. | $215.27 | -3.63% | $87.1B |
| TECH | Bio-Techne Corp | $72.79 | -0.01% | $11.4B |
| HALO | Halozyme Therapeutics Inc. | $96.50 | -3.76% | $11.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier